

Anussara Prayongrat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2863293/publications.pdf>

Version: 2024-02-01

26
papers

315
citations

840119

11
h-index

887659

17
g-index

26
all docs

26
docs citations

26
times ranked

632
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 375-385.	1.0	30
2	Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. <i>Journal of Radiation Research</i> , 2017, 58, 509-516.	0.8	28
3	Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. <i>Advances in Radiation Oncology</i> , 2017, 2, 301-307.	0.6	28
4	Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. <i>Journal of Radiation Research</i> , 2018, 59, i2-i10.	0.8	28
5	A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. <i>Radiation Oncology</i> , 2015, 10, 166.	1.2	26
6	Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. <i>Journal of Radiation Research</i> , 2018, 59, 446-455.	0.8	26
7	The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. <i>Radiotherapy and Oncology</i> , 2019, 135, 100-106.	0.3	18
8	Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. <i>Radiology and Oncology</i> , 2015, 49, 155-162.	0.6	15
9	Optimal plasma pretreatment EBV DNA cut-off point for nasopharyngeal cancer patients treated with intensity modulated radiation therapy. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 467-475.	0.6	15
10	Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. <i>Scientific Reports</i> , 2017, 7, 42624.	1.6	14
11	Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy. <i>Radiology and Oncology</i> , 2018, 52, 195-203.	0.6	14
12	High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , 2017, 8, 219-228.	0.8	11
13	Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1100-1113.	0.6	10
14	Present developments in reaching an international consensus for a model-based approach to particle beam therapy. <i>Journal of Radiation Research</i> , 2018, 59, i72-i76.	0.8	8
15	Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system. <i>Journal of Radiation Research</i> , 2018, 59, i63-i71.	0.8	8
16	Long-term patient-rated cosmetic and satisfactory outcomes of early breast cancer treated with conventional versus hypofractionated breast irradiation with simultaneous integrated boost technique. <i>Breast Journal</i> , 2020, 26, 1946-1952.	0.4	7
17	Tumor Prognostic Prediction of Nasopharyngeal Carcinoma Using CT-Based Radiomics in Non-Chinese Patients. <i>Frontiers in Oncology</i> , 2022, 12, 775248.	1.3	5
18	Assessing the uncertainty in a normal tissue complication probability difference ($\Delta NTCP$): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. <i>Journal of Radiation Research</i> , 2018, 59, i50-i57.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Hypothyroidism after radiotherapy for nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 4, 3-3.	0.5	4
20	The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer?. <i>Clinical Lung Cancer</i> , 2018, 19, 289-293.	1.1	3
21	Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. <i>Neuro-Oncology Practice</i> , 2018, 5, 37-45.	1.0	3
22	Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 221-228.	0.3	3
23	Flattening filter free stereotactic body radiation therapy for lung tumors: outcomes and predictive factors. <i>Translational Cancer Research</i> , 2021, 10, 571-580.	0.4	2
24	Assessment of the confidence interval in the multivariable normal tissue complication probability model for predicting radiation-induced liver disease in primary liver cancer. <i>Journal of Radiation Research</i> , 2021, 62, 483-493.	0.8	2
25	Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 51-56.	1.2	2
26	BMET-32 OUTCOMES OF GAMMA KNIFE RADIOSURGERY IN BRAIN METASTASES FROM NEUROENDOCRINE TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v52.1-v52.	0.6	1